Amedisys Inc (NASDAQ:AMED) Insider David L. Kemmerly Sells 8,125 Shares

Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 8,125 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $117.77, for a total transaction of $956,881.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

David L. Kemmerly also recently made the following trade(s):

  • On Thursday, May 30th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $113.48, for a total transaction of $567,400.00.
  • On Monday, May 20th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $109.96, for a total transaction of $549,800.00.
  • On Friday, May 10th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $115.17, for a total transaction of $575,850.00.
  • On Tuesday, May 7th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $118.20, for a total transaction of $591,000.00.

Shares of AMED traded up $0.44 during midday trading on Wednesday, hitting $118.04. The stock had a trading volume of 281,027 shares, compared to its average volume of 452,808. Amedisys Inc has a 1 year low of $80.13 and a 1 year high of $140.91. The company has a market cap of $3.70 billion, a P/E ratio of 32.52, a P/E/G ratio of 1.44 and a beta of 1.40. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.69.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The business had revenue of $467.34 million for the quarter, compared to the consensus estimate of $460.83 million. During the same quarter in the prior year, the firm posted $0.79 earnings per share. The business’s revenue for the quarter was up 17.0% on a year-over-year basis. Analysts predict that Amedisys Inc will post 4.08 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC raised its stake in shares of Amedisys by 2.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 3,704 shares of the health services provider’s stock valued at $433,000 after acquiring an additional 95 shares during the period. Jennison Associates LLC raised its stake in shares of Amedisys by 2.0% in the fourth quarter. Jennison Associates LLC now owns 6,408 shares of the health services provider’s stock valued at $750,000 after acquiring an additional 126 shares during the period. Alpha Quant Advisors LLC raised its stake in shares of Amedisys by 137.0% in the first quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after acquiring an additional 137 shares during the period. ETRADE Capital Management LLC raised its stake in shares of Amedisys by 2.2% in the fourth quarter. ETRADE Capital Management LLC now owns 6,819 shares of the health services provider’s stock valued at $799,000 after acquiring an additional 148 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Amedisys by 9.9% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,813 shares of the health services provider’s stock valued at $222,000 after acquiring an additional 164 shares during the period. 86.30% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently issued reports on AMED shares. SunTrust Banks upped their price target on shares of Amedisys to $145.00 and gave the company a “buy” rating in a research note on Friday, March 1st. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. ValuEngine downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 27th. Barclays upped their price target on shares of Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, March 21st. Finally, Craig Hallum decreased their price target on shares of Amedisys from $132.00 to $124.00 and set a “hold” rating on the stock in a research note on Friday, March 1st. They noted that the move was a valuation call. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $129.89.

TRADEMARK VIOLATION WARNING: “Amedisys Inc (NASDAQ:AMED) Insider David L. Kemmerly Sells 8,125 Shares” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2019/06/12/amedisys-inc-nasdaqamed-insider-david-l-kemmerly-sells-8125-shares.html.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: What are the FAANG Stocks?

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.